Loading data for BLCO — first visit, this takes a few seconds.

Bausch + Lomb Corporation (BLCO)

NYSE: BLCO · Real-Time Price · USD

18.00

+0.12 (0.67%)

At close: Sep 02, 2026, 3:11 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	17
Market Cap	6.52B
Revenue (ttm)	5.32B
Net Income (ttm)	-171M
	0.55
	-0.48
	n/a
	16.69
P/B (ttm)	1.01
P/S (ttm)	1.22
Earnings Date	Oct 28, 2026

Ask	18.49
Volume	358,602
Avg. Volume (20D)	409,746
Open	17.94
Previous Close	17.88
Day's Range	17.86 - 18.46
52-Week Range	13.77 - 18.91
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About BLCO

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; a...

[Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

IPO Date May 6, 2022

Employees 13,000

Stock Exchange NYSE

Ticker Symbol BLCO

Website https://www.bausch.com

Full Company Profile

Financial Performance

In 2025, Bausch + Lomb's revenue was 5.1B, an increase of 6.47% compared to the previous year's 4.79B. Earnings were -360M, an increase of 13.56%.

Financial Statements

Earnings Surprise

Bausch + Lomb has released their quarterly earnings on Jul 29, 2026:

Revenue of $1.39B misses estimates by $0, with 9.08% YoY growth.
EPS of 0.16 misses estimates by 0.00, with 128.57% YoY growth.

Next Earnings Release

Bausch + Lomb Corporation is scheduled to release its earnings on Oct 28, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

4 days ago · Simply Wall St.

Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers

Bausch + Lomb stock has delivered a 17.2% return over the past year, yet several valuation checks still flag the shares as cheap relative to an intrinsic value estimate and to market multiples. For in...

5 days ago · StockStory

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other busine...

6 days ago · StockStory

3 Healthcare Stocks We Steer Clear Of

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare st...

1 week ago · BioPharma Dive

Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

1 week ago · StockStory

A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Bausch + Lomb (NYSE:BL...

Page 1 of 2

Bausch + Lomb Corporation (BLCO)